PLUS vs QUBT

The company presents a stark dichotomy between strong growth and deteriorating fundamental health, evidenced by a weak Piotroski F-Score of 2/9. While the stock is attractively valued with a PEG ratio of 0.82 and trades well below its growth-based intrinsic value of $165.2, the deterministic health markers and bearish technical trend suggest underlying instability. Strong revenue and earnings growth are currently offsetting these risks, but the low F-Score indicates a need for caution regarding cash flow or operational efficiency.

The company exhibits critical fundamental weakness, highlighted by a Piotroski F-Score of 0/9, indicating severe financial distress across all health metrics. While revenue growth is nominally high at 219.40%, the Price-to-Sales ratio of 3150.78 is an extreme outlier, suggesting the market capitalization is completely decoupled from current revenue generation. Operating margins are catastrophic at -11220.20%, and insider sentiment is bearish with recent sales from the COO and General Counsel. Despite a bullish analyst target price of $17.40, the deterministic data suggests a highly speculative asset with no current fundamental floor.